Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase NA 3Phase 1/2 3Phase 4 2Phase 3 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Metastatic Breast Cancer 1Breast Neoplasms 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER × disitamab vedotin × Clear all
NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT05904964 2023-06-22

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
288 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡